Literature DB >> 29061403

Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management.

Raj Velamoor1.   

Abstract

Neuroleptic Malignant Syndrome (NMS) is a life threatening complication of antipsychotic therapy. It is often assumed to be rare. Observations suggest that rather than overestimating its frequency, we are more likely to underestimate it (Pope et al., 1986). It is a rare but potentially fatal disorder characterized by four principal symptoms. These are mental status changes, muscle rigidity, hyperthermia, and autonomic dysfunction. The diagnosis of NMS often presents a challenge because several medical conditions generate similar symptoms. Although less common now than in the past, thanks to greater awareness, it remains a risk in susceptible patients receiving conventional or atypical neuroleptics. Reducing the risk factors, early recognition of suspected cases, and prompt management can significantly reduce morbidity and mortality of this dangerous condition. Collaboration between psychiatry and other medical specialities may be the key to a successful outcome.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autonomic dysfunction; Consensus criteria; Dopamine agonists; Dopamine blockade; Hyperthermia; Management; Mental status change; Rigidity; Risk factors

Mesh:

Year:  2017        PMID: 29061403     DOI: 10.1016/j.ajp.2017.05.004

Source DB:  PubMed          Journal:  Asian J Psychiatr        ISSN: 1876-2018


  11 in total

1.  Silent Neuroleptic Malignant Syndrome: A Case Report of Atypical Antipsychotic Induced Elevation of Creatinine Kinase and Altered Mental Status.

Authors:  Amber N Edinoff; Hamza Mohammad-Amin; Amira S Odisho
Journal:  Health Psychol Res       Date:  2022-08-20

2.  Atypical Neuroleptic Malignant Syndrome Induced by Low Dose Quetiapine in a Patient Treated with Donepezil.

Authors:  Elçin Özçelik Eroğlu; M İrem Yildiz; M Kâzım Yazici
Journal:  Noro Psikiyatr Ars       Date:  2021-06-03       Impact factor: 1.339

3.  Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.

Authors:  Daniel Guinart; Heidi Taipale; Jose M Rubio; Antti Tanskanen; Christoph U Correll; Jari Tiihonen; John M Kane
Journal:  Schizophr Bull       Date:  2021-10-21       Impact factor: 9.306

4.  Neuroleptic Malignant Syndrome in a Patient With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Case Report and Review of Related Literature.

Authors:  Robert Joseph C Sarmiento; Jose Danilo B Diestro; Athena Kate D Antonio; Mario B Prado; Karen Joy B Adiao; Carissa Paz Dioquino-Maligaso
Journal:  Neurohospitalist       Date:  2021-03-19

Review 5.  Anti-N-methyl-D-aspartate receptor encephalitis mimics neuroleptic malignant syndrome: case report and literature review.

Authors:  Hai-Yang Wang; Tian Li; Xue-Lin Li; Xiao-Xia Zhang; Zhong-Rui Yan; Yang Xu
Journal:  Neuropsychiatr Dis Treat       Date:  2019-04-02       Impact factor: 2.570

6.  Neuroleptic malignant-like syndrome associated multiple system atrophy: report on three cases.

Authors:  Yan Lin; Lin Ma; Nan Zhang; Ruihua Li; Wenjing Jiang
Journal:  BMC Neurol       Date:  2022-02-25       Impact factor: 2.474

7.  Atypical Neuroleptic Malignant Syndrome in a COVID-19 Intensive Care Unit.

Authors:  Joshua R Durbach; Gerald Rosen; Carolina De La Cuesta; Seth Gottlieb
Journal:  Cureus       Date:  2022-08-12

Review 8.  Treatment Options for Acute Agitation in Psychiatric Patients: Theoretical and Empirical Evidence.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Cureus       Date:  2019-11-14

9.  Neuroleptic malignant syndrome with abnormally elevated cardiac troponin I: a case report.

Authors:  Qiang Wang; Jiabo Shi; Peng Zhao; Qiuyun Cao; Zhijian Yao
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

Review 10.  Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone.

Authors:  Paula Soria-Chacartegui; Gonzalo Villapalos-García; Pablo Zubiaur; Francisco Abad-Santos; Dora Koller
Journal:  Front Pharmacol       Date:  2021-07-14       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.